This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Actinium Pharmaceuticals Sponsors Webinar On Clinical Use Of Alpha Immunotherapy

NEW YORK, Nov. 27, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. will sponsor a webinar on the "Promise of Alpha Therapy".  The discussion will be broadcast and can be accessed via the link http://www.veomed.com/grandrounds?gnr=871099 on November 30, 2012 at 3:00 PM and followed by questions and answers session from the audience.  Participants will discuss their personal experience, both clinical and pre-clinical, with alpha particle immunotherapy platform-based drug candidates.  The discussion is moderated by Dr. Rosemary Mazanet and participants include Dr. David Scheinberg, Chairman, and Experimental Therapeutics Center at Memorial Sloan Kettering Cancer Center, Dr. Joseph Jurcic, Associate Attending Physician at Sloan-Kettering's Department of Leukemia and Dr. Steven Larson, Vice Chair for Research, Department of Radiology at Sloan Kettering. 

The focus of the webinar is the use of alpha radioimmunotherapy in clinical trials and preclinical models.  Dr. Scheinberg, who originated the idea of alpha immunotherapy, will discuss theoretical underpinnings of the approach and results of his preclinical experiments.  Dr. Jurcic is currently treating acute myeloid leukemia (AML) patients in clinical trials with alpha immunotherapy drug candidates and he will present his experience and results.  As a participant in clinical trials from the nuclear medicine side, Dr. Larson will provide a first-hand account on the ease of use and requirements for alpha immunotherapy.  All participants will also offer their views on the future prospects of drugs based on this platform technology. The panel discussion to be broadcast on November 30 at 3:00 PM Eastern Time, questions for participants may be submitted via apharma@actiniumpharmaceuticals.com or by phone, the details for which are as below:

Phone number: +1 (213) 493-0614Access Code: 157-776-237

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,654.77 +369.26 2.27%
S&P 500 1,987.66 +47.15 2.43%
NASDAQ 4,812.7080 +115.1720 2.45%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs